The U.S. Food and Drug Administration Approves Zanubrutinib for Waldenstrӧm Macroglobulinemia
On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).
The drug had previously been approved for the treatment of mantle cell lymphoma (MCL) in adults patients who have received at least one prior therapy.
“Each lymphoma patient’s experience is unique, and the approval of zanubrutinib offers patients with Waldenstrӧm macroglobulinemia a new treatment option and new opportunity for hope,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “Chemotherapy-free agents and new methods of administration are important to ensuring that patients and their physicians, through shared decision making, are able to access the right treatments at the right time.”
Learn About: Oral Agents in Lymphoma
Currently, there are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma that can be taken by mouth, either in liquid or tablet/capsule form. Oral agents are just as effective and can have similar side effects as anticancer drugs that are given intravenously.